Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yinghao Wu
Observed names:
Y.-L. Wu,
YiChun Wu
Institutions:
Beijing University of Chinese Medicine,
Shanghai Jiao Tong University,
Shanghai Sixth People's Hospital
Observed institutions:
Beijing University of Chinese Medicine,
Shanghai Jiao Tong University,
Shanghai Sixth People's Hospital,
Guangdong Academy of Medical Sciences,
Guangdong Provincial People's Hospital,
Junshi Biosciences (China),
Southern Medical University
show all 7
ORCID:
0009-0005-9867-6213
Observed ORCID:
0009-0005-9867-6213
OpenAlex ID:
A5024468617
Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
·
Clinical Cancer Research
·
20
Spontaneous dynamic modulation of ionic/immune microenvironment on polyetheretherketone for sequential anti-infection and osseointegration
2025
·
Junjie Zhou
, Yinghao Wu
, et al.
·
Bioactive Materials
·
12
Bifidobacterium depletion promotes goiter via gut-thyroid axis: evidence from Mendelian randomization and experimental validation
2025
·
Wenyong Liao
, Yang Jiang
, et al.
·
Frontiers in Microbiology
·
8
PDF
Piezoelectric Ceramic Nanofiber Aerogels Direct Neutrophil Fate for Diabetic Tissue Regeneration
2026
·
Jibing He
, Yinghao Wu
, et al.
·
Advanced Materials
·
7
Near‐Infrared Switch‐Driven Macrophage Dynamically Reprogramming for Anti‐Infection and Tissue Healing on Polyetheretherketone Implants
2025
·
Yinghao Wu
, Shuaiqi Jiang
, et al.
·
Advanced Science
·
7
OA06.03 SAFFRON-301: Tislelizumab Plus Sitravatinib in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1
2024
·
Q. Zhou
, B. Gao
, et al.
·
Journal of Thoracic Oncology
·
5
PDF
Perioperative SARS-CoV-2 infection and postoperative complications: a single-centre retrospective cohort study in China
2025
·
Jia Zhan
, Fei Zhong
, et al.
·
BMJ Open
·
4
LBA2 Phase II study of PD-L1 expression guidance on neoadjuvant (NA) nivolumab (Nivo) monotherapy with or without platinum-doublet chemotherapy in resectable NSCLC
2022
·
S.-Y. Liu
, S. Dong
, et al.
·
Immuno-Oncology Technology
·
3
Haizao Yuhu Decoction alleviates goiter via the gut-thyroid axis: Microbiota-derived SCFAs promote hormone synthesis and restore apoptosis
2026
·
Wenyong Liao
, Jie Gao
, et al.
·
Phytomedicine
·
1
EP08.01-085 Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
2022
·
S.-Y. Liu
, Q. Zhou
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
Haizao Yuhu Decoction Inhibits Goiter via p53 Pathway‐Induced Apoptosis: Metabolomic and Cellular Assay Analysis
2026
·
Xiaoqing Liu
, Wenyong Liao
, et al.
·
Biomedical Chromatography
P4.11E.16 Clinical Outcome of HER2-mut NSCLC Treated with First-Line Immunotherapy-Based Regimens versus Chemotherapy/HER2-TKIs
2024
·
K. Yin
, L.-P. Chen
, et al.
·
Journal of Thoracic Oncology
PDF
P1.08B.01 Predicting Tumor Recurrence Risk in Locally Advanced NSCLC with Detectable ctDNA-Based Molecular Residual Disease: An Xgboost Model Analysis
2024
·
Y. Pan
, J.-T. Zhang
, et al.
·
Journal of Thoracic Oncology
PDF
Supplementary Figure S2 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Figure S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
PDF
Supplementary Table S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Methods S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
PDF
Supplementary Figure S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Table S2 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
PDF
Data from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Figure S3 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Data from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Supplementary Table S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
2024
·
Yajin Chen
, Chengyou Du
, et al.
Show more works
View as search
Works count:
23
Citation count:
68
H-index:
5
I10-index:
2
Year
Topic
Type